Breaking News

GSK Invests $120M in Next-Gen US Bio Manufacturing Facility

Part of nearly $400 million in US manufacturing investments to deliver on the company’s pipeline

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GSK has unveiled a $120 million investment to expand its manufacturing facility in Upper Merion, PA that will support the delivery of the company’s pipeline. The investment at Upper Merion creates a technologically-advanced manufacturing hub that offers the flexibility and speed necessary when making today’s complex specialty medicines.   “These investments will support and accelerate the transformation of our pipeline to deliver the next generation of medicines and vaccines for patients who n...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters